{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"50"},{"groupId":"OG002","value":"16"}],"units":"Participants"}],"description":"Anti-SARS-CoV2 IgG antibody seroconversion from negative to positive.","groups":[{"description":"Multiple myeloma and amyloidosis patients who did not develop an anti-spike antibody titer of \\>1 S/CO after prior COVID-19 vaccination.","id":"OG000","title":"Cohort 1"},{"description":"Patients with other hematologic malignancies who did not develop an anti-spike antibody titer of \\>1 S/CO after prior COVID-19 vaccination.","id":"OG001","title":"Cohort 2"},{"description":"Patients with multiple myeloma, amyloidosis, or other hematologic malignancy who had a \"weak positive\" response to prior COVID-19 vaccine, defined as an anti-spike antibody titer of 1-2 S/CO.","id":"OG002","title":"Cohort 3"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants who received a single dose of the Moderna mRNA COVID-19 vaccine administered intramuscularly.","reportingStatus":"POSTED","timeFrame":"28 days (+/- 3 days) following a booster dose of the Moderna mRNA COVID-19 vaccine","title":"Observed Response Rate of Anti-SARS-CoV2 Antibody Seroconversion.","type":"PRIMARY","unitOfMeasure":"Participants"}